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Abstract
Intravenous immunoglobulin has long been used in treating autoimmune diseases, although mechanisms remain uncertain.
Activating Fcc receptors are receptors of IgG and reported to be essential in intravenous immunoglobulin (IVIG) therapy.
Therefore, we hypothesized natural killer (NK) cells, which express abundant activating Fcc receptors, are the potential
cellular target. In experimental autoimmune encephalomyelitis (EAE), we demonstrated that IgG suppressed disease
development in intact, but not in NK cell depleted mice. Adoptive transfer of IgG-treated NK cell could protect mice against
EAE, and suppressed interferon c and interleukin 17 production. The percentage of CD4+Foxp3+ regulatory T cells was
significantly increased. The increase of regulatory T cells was also observed in IgG-treated EAE mice but not in NK cell
depleted mice. In vitro experiments confirmed that IgG-treated NK cells enhanced regulatory T cell induction from naı¨ve
CD4+ T cells. Interestingly, cells from draining lymph nodes produced more interleukin 2 after the adoptive transfer of IgG-
treated NK cells. We neutralized interleukin 2 and the induction of CD4+Foxp3+ T cells by IgG-treated NK cells was
significantly reduced. To our knowledge, we identified for the first time the critical role of NK cells in the mechanism of IgG-
induced induction of Treg cells in treatment of autoimmunity.
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Background
Intravenous immunoglobulin (IVIG) is IgG purified from
pooled blood plasma of healthy donors. Its administration was
originally designed as replacement therapy for antibody deficien-
cies [1]. Since then, high dose IVIG has been established as an
important treatment of autoimmune diseases including multiple
sclerosis, chronic inflammatory demyelinating polyneuropathy,
Guillain-Barr’e syndrome and myasthenia gravis [1]. The
protective effects of IVIG were also reported in animal studies
including experimental autoimmune encephalomyelitis (EAE) [2],
arthritis [3] and type I diabetes [4]. Although the use and
beneficial effects of IVIG in autoimmune diseases are well
documented, the mechanisms remain unclear. Fcc receptors were
suggested as the potential target for IVIG treatment, as they are
the receptors of IgG [1]. Siragam et al. confirmed the critical role
of activating Fcc receptors in the anti-inflammatory effects of
IVIG in vivo [5]. In an invariant NKT(iNKT) cell-mediated
allergic airway inflammation model, IVIG regulates iNKT cells
through activating Fcc receptor, FccRIIIa [6]. A recent study also
confirmed that the inhibitory effect of IVIG on T cells responses is
independent of the inhibitory receptor FccRIIb, supporting the
role of activating Fcc receptors in IVIG therapy [7]. Therefore,
cells expressing activating Fcc receptor could be the cellular
targets for IVIG treatment.
Natural killer (NK) cells were previously thought as the effectors
in innate immunity in direct killing of transformed and virus
infected cells. They are responsible for triggering inflammation by
releasing pro-inflammatory cytokines and chemokines rapidly.
However, more recent studies found that they can reciprocally
interact with dendritic cells (DCs) [8] and regulate adaptive
immunity by modulating T cell proliferation and polarization
[9,10]. More recent data also suggest that NK cells are capable of
interacting with both regulatory T (Treg) cells and B cells [11,12].
As NK cells express high level of activating Fcc receptors that
could recognize IgG [13], we hypothesized that NK cells are the
cellular targets for IVIG treatment in regulating T cell immune
responses and hence, T cell mediated autoimmune diseases. Using
EAE as an in vivo T cell-mediated autoimmune animal model, we
found that high dose of human IgG treatment protected mice from
EAE but was ineffective in NK cell depleted mice. Conversely,
adoptive transfer of IgG-treated NK (IgG-NK) cells could suppress
EAE through induction of CD4+Foxp3+ Treg cells. Our in vitro
experiments further demonstrated that IgG-treated NK cells
induced CD4+Foxp3+ Treg cells in the presence of interleukin
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(IL)-2 and transforming growth factor (TGF)-b1, providing a
mechanistic basis for this phenomenon.
Results
IgG protects mice from EAE and suppresses their IL-17
and IFN-c production in normal, but not in NK cell-
depleted mice
To test our hypothesis that NK cells are the cellular targets for
IVIG treatment, we first determined whether NK cells are
required for efficacy of IgG treatment against EAE. Treatment
with anti-asialo GM1 antibody depleted more than 90% of NK
cells in different tissues, i.e. blood, spleen and lymph nodes, as
confirmed by FACS (Figure S1). We then applied 2 doses of high
dose of human IgG to EAE mice with or without NK cell
depletion by anti-asialo GM1 antibody on day 0 and 4 relative to
immunization. As reported previously, 2 doses of IgG treatments
could significantly suppress EAE development [14]. IgG could
significantly suppress EAE in our experiments, confirming these
data. Importantly, EAE protection was not observed in NK cell
depleted mice (p,0.01, Figure 1A). To demonstrate the protective
effect is specific for IgG, we compared EAE development in IgG
treated group to a control group that is treated with another serum
protein, i.e. BSA. We observed that BSA treated EAE mice also
developed severe EAE (Figure S2) but not in IgG treated mice.
It has been reported that IVIG could suppress the production of
two known pathogenic cytokines, IL-17 and interferon (IFN)-c, in
EAE mice [15]. At day 10, we isolated the cells from draining
lymph nodes of EAE mice with or without NK cell depletion after
IgG treatment and studied their MOG35–55 specific IL-17 and
IFN-c production. We found that both these pathogenic cytokines
were suppressed after IgG treatment but again, this was not
observed in NK cell-depleted mice (p,0.05, Figure 1B). Collec-
tively, our data are consistent with observations of previous studies
[2,14,15] that IgG could suppress EAE as well as the production of
pathogenic cytokines. Importantly, we demonstrated that this
suppression requires the presence of NK cells.
Adoptive transfer of IgG-NK cells suppresses disease
development, as well as IL-17 and IFN-c production in
EAE
We next hypothesized that IgG-NK cells alone would also
suppress EAE. We isolated NK cells from the spleen of naı¨ve
C57BL/6N mice and pre-treated them with IgG and adoptively
transferred 16106 IgG-NK cells or untreated NK cells to mice at
the day of EAE immunization. Interestingly, we observed that
IgG-NK cells protected mice from EAE similarly to IgG treatment
(p,0.01, Figure 2A) but untreated NK cells did not.
Both Th17 and Th1 effector responses are involved in EAE
development [16–18]. Therefore, we examined the antigen
specific cytokine productions of IL-17 and IFN-c to MOG35–55
of EAE mice after adoptive transfer of IgG-NK cells. We isolated
cells from the draining lymph nodes and stimulated them with
MOG35–55. Both IL-17 and IFN-c production was significantly
reduced after IVIG- NK cell infusion (p,0.05, Figure 2B) but no
significant reduction was observed after adoptive transfer of
untreated NK cells (p.0.05, Figure 2B). For production of other
cytokines that are involved in inflammation and T cell polariza-
tion, i.e. IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-a and
transforming growth factor (TGF)-b1, no statistically significant
difference was observed (Figure S3) between responses of IgG-NK
vs NK infused mice.
IgG and IgG-NK cells treatments reduce demyelination in
EAE mice
Toluidine blue staining sections were used to investigate the
demyelination of EAE mice with different treatments (Figure S4).
Demyelination was apparent in untreated EAE mice (Figure S4A)
but not in IgG-treated EAE mice (Figure S4B). However,
demyelination was present in NK cell depleted mice despite IgG
treatment (Figure S4D). This further confirms the importance of
NK cells in IgG treatment in vivo. Conversely, in EAE mice that
received adoptive transfer of IgG-NK cells (Figure S4F), more
myelinated axons were found when compared with control EAE
mice. These observations are in line with data in Figure 1 and 2
that clinical manifestations of EAE were suppressed in mice after
these two treatments.
IgG induces CD4+Foxp3+ Treg cells in EAE mice and it
requires NK cells
A previous study reported that IgG suppresses EAE by inducing
Treg cells [15]. We confirmed that IgG could induce CD4+Foxp3+
Treg cells in EAE mice (p, 0.05, Figure 3). However, this increase
was not observed in EAE mice after NK cell depletion (p,0.05,
Figure 1. IgG protects NK sufficient, but not NK depleted mice
from EAE and lowers associated immunological responses. EAE
was induced in C57BL/6N mice as described in Materials and Methods.
IgG was injected intravenously at day 0 and 4. NK cell was depleted in
EAE mice with or without IgG treatment by injecting anti-asialo GM1
antibody intravenously 1 day before and 3 days after the immunization.
(A) EAE development. NK depleted or non-depleted mice were
followed for EAE and disease was scored as described in Methods
(n = 16–20). (B) Cytokine production. On day 10, cells were isolated
from draining lymph nodes. 2.56106 isolated cells were re-stimulated
with MOG35–55 (20 mg/ml) for 72 hours. Supernatant was collected and
cytokine production was determined (n = 4–7). Data are pooled from 4
independent experiments (A) and 2 independent experiments (B) and
displayed as mean 6 SEM. *: p,0.05; **: p,0.01, Krusaki-Wallis test.
doi:10.1371/journal.pone.0060862.g001
IgG-NK Induces Treg to Suppress EAE
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Figure 3), which supports that IgG therapy requires the presence
of NK cells and suggests that IgG acts through NK cells to induce
Tregs.
We next examined the levels of CD4+Foxp3+ Treg cells in
draining lymph nodes of EAE mice after adoptive transfer of IgG-
NK cells. We also observed that there is increase of Treg cells after
adoptive transfer of IgG-NK cells (Figure 4A, B) but not in the
case of adoptive transfer of NK cells not treated with IgG.
IgG-NK induced Treg cells are suppressive and are
responsible for protection from EAE
We investigated the suppressive function of Treg cells in EAE
mice after adoptive transfer of IgG-NK cells. We sorted
CD4+CD25hi Treg cells (.95% express Foxp3, Figure S5) from
spleens of EAE mice that had received, or not, an adoptive transfer
of untreated NK cells or IgG-NK cells, and cultured these Treg
cells with carboxyfluorescein diacetate succinimidyl ester (CFSE)
labeled CD4+CD252 T cells from spleens of untreated EAE mice,
antigen presenting cells (irradiated CD42 splenocytes from naı¨ve
mice) and MOG35–55. As shown in Figure 4C and D, Treg cells
from untreated (TregEAE) and NK cell treated (TregNK-EAE) EAE
mice suppressed the cell division of CD4+ T cells from 31% to
16.97% and 14.73% respectively (Figure 4D), at a 1:0.5 ratio of
CD4+ T cells to Treg cells. While Treg cells from EAE mice with
adoptive transfer of IgG-NK cells (TregIgG-NK-EAE) are slightly
more potent in suppressing the cell division (11.7362.36%,
p,0.05, Figure 4D).
A previous study reported that the beneficial effect of IgG in
EAE depend on increasing Treg cells [15]. We therefore
investigated whether IgG-NK cell protection from EAE is
dependent on Treg cells. To address this, we depleted Treg cells
by using a monoclonal anti-CD25 antibody (clone PC61) in EAE
mice with adoptive transfer of IgG-NK cells. More than 90% of
Treg cells were depleted in different tissues, i.e. blood, spleen and
lymph nodes, as confirmed by flow cytometry (Figure S6). We
observed that Treg depletion completely abrogated the protective
effect of IgG-NK cells (Figure 4E). Collectively, our data suggest
that IgG-NK cells increase the number (Figure 4A and B) and a
marginal increase in suppressive function (Figure 4C and D) of
Treg cells in vivo and that Treg cells are required for the observed
protective effect of IgG-NK cells on EAE (Figure 4E).
NK cells also expressed CD25, although the expression level is
much lower than Treg cells, so anti-CD25 antibody treatment
may also deplete NK cells. To address this issue, we injected mice
with anti-CD25 antibody and compared their NK cell percentage
to mice that received isotype control at day 3, 5 and 7. We
observed that the percentages of NK cells in lymph nodes and
spleen were not changed after anti-CD25 antibody treatment
(Data not shown).
IgG-NK cells increase IL-2 production during antigen
specific T cell responses and the expression of IL-2
receptor a, CD25, in Treg cells
IL-2 is an important cytokine for maintenance, induction and
expansion of CD4+CD25+ Treg cells [19]. IL-10 and TGF-b1 are
also included as they are important in Treg cell induction [20]. To
address the mechanism involved in expansion of Treg cells by IgG
in EAE mice, we studied the production of IL-2, IL-10 and TGF-
b1 during specific T cell responses to MOG35–55.
After culture with MOG35–55, cells from draining lymph nodes
of EAE mice that had been infused with IgG-NK cells produced
high levels of IL-2 (Figure 5A), while production of TGF-b1 and
IL-10 was not appreciably changed (Figure S3). TregIgG-NK-EAE
had higher expression of IL-2 receptor a, i.e. CD25, than TregEAE
(Figure 5B). This indicated that TregIgG-NK-EAE may be more
responsive to IL-2 mediated expansion/survival. All these data
suggested that enhanced levels of IL-2 may be involved in the
increase of Treg cells observed as a result of IgG-NK cell
treatment.
IgG-NK cells convert naı¨ve T cells to Tregs through a
process requiring IL-2 and TGF-b1
To further investigate the mechanism how IgG-NK cells induce
Treg cells, we performed the following in vitro experiments.
Because TGF-b1 is required for the induction of Treg cells from
naı¨ve CD4+ T cells in mice [20], we cocultured IgG-NK cells with
naı¨ve CD4+ T cells and a low dose of TGF-b1 (0.1 ng/ml) with
anti-CD3 and anti-CD28 stimulation. The reason for keeping
TGF-b1 in low concentration is that high dose of TGF-b1 may
mask the need for other factors in induction of Treg cells. After 4
days of culture, naı¨ve CD4+ T cells cultured with IgG-NK
expressed Foxp3, the lineage-specific transcription factor for Treg
cells, in the presence, but not in the absence, of TGF-b1
Figure 2. Adoptive transfer of IgG-NK cell suppresses EAE. EAE
was induced in C57BL/6N mice. NK cells were isolated from the spleen
of naı¨ve mice and incubated with IgG for 18 hours. 16106 of IgG-NK
cells or untreated-NK cells were injected intravenously on the day of
EAE induction. (A) The mean clinical scores were significantly decreased
after injection of IgG-NK cell when compared with untreated EAE mice
(p,0.01). No significant difference was observed between untreated
EAE mice and EAE mice with adoptive transfer of untreated-NK cells
(n = 10–11). (B) At day 10, cells were isolated from draining LNs. 2.56106
isolated cells were re-stimulated with MOG35–55 for 72 hours. Cytokine
productions were determined (n = 4–7). Data are pooled from 3
independent experiments (A) and 2 independent experiments (B)
and displayed as mean6 SEM. *: p,0.05; **: p,0.01, Krusaki-Wallis test.
doi:10.1371/journal.pone.0060862.g002
IgG-NK Induces Treg to Suppress EAE
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e60862
(Figure 6A). We also observed the increase of Foxp3 expression in
CD4+ T cells after coculture with IgG-untreated NK cells,
although it is not as marked as IgG-NK cells (Figure 6A).
Since there was an increase of IL-2 production in EAE mice
with IgG-NK cell treatment and TregIgG-NK-EAE expressed higher
IL-2 receptor a (Figure 5B), we investigated the role of IL-2 in
inducing Tregs cells by IgG-NK cells. We blocked IL-2 activity by
using IL-2 neutralization antibody. We observed that the Foxp3
expression was significantly reduced (Figure 6B). Therefore, these
in vitro experiments confirmed that IgG-NK cells induce Treg cells
from naı¨ve CD4+ T cells in the presence of TGF-b1 and IL-2 and
support the conclusion that NK cells are required during IgG
treatment (Figure 1) because they are responsible for inducing
Treg cells in vivo (Figure 3).
CD4+CD25hi Treg cells induced by IgG-NK cells
suppressed T cell proliferation
To investigate the inhibitory function of the Treg cells induced
by IgG-NK cells, sorted CD4+CD25hi Treg cells were cocultured
with CFSE labeled naı¨ve CD4+CD62L+ T cells. Plate bound anti-
CD3 and anti-CD28 antibodies were used to stimulate naı¨ve T
cells proliferation. We observed that IgG-NK cell induced Treg
cells significantly suppressed naı¨ve T cell proliferation (Figure 7).
Figure 3. IgG could not induce CD4+Foxp3+ Treg cells in NK cell-depleted EAE mice. (A, B) EAE was induced in C57BL/6N mice. IgG was
injected intravenously at day 0 and 4. NK cell was depleted in EAE mice with or without IgG treatment by injecting anti-asialo GM1 antibody
intravenously 1 day before and 3 day after the immunization. Cells were isolated from draining lymph nodes of EAE mice 10 days after EAE induction.
Anti-CD4 antibody was used to stain the surface expression of CD4. Foxp3 expression on gated CD4 cells was determined by intracellular staining.
Mice: n = 6 per group. Data are representative of at least 2 independent experiments and displayed as the mean 6 SEM. Krusaki-Wallis test was used
for comparison. *: p,0.05.
doi:10.1371/journal.pone.0060862.g003
IgG-NK Induces Treg to Suppress EAE
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Discussion
In this study, we report 2 novel findings. First, we demonstrated
that the protective effect of IgG in the development of EAE in
mice depends on the presence of NK cells. This observation may
be of relevance to treatment of human autoimmune diseases by
IVIG. The percentage of NK cells in circulating lymphocytes
varies from ,5 to ,20% in humans [21] and the level of NK cells
could conceivably constitute a contributing factor for the efficacy
of IVIG treatment.
The induction of CD4+Foxp3+ Treg cells by IgG-NK cells is our
second novel finding. By in vitro study, we presented evidence that
IgG-NK cells are able to induce CD4+Foxp3+ Treg cells from
naı¨ve CD4+ T cells and that it is dependent on IL-2 and TGF-b1
(Figure 6). Although we identified the cytokines required for
inducing Treg by NK cells, T cell co-stimulatory molecules
Figure 4. IgG-NK cells suppress EAE by inducing CD4+Foxp3+ Treg cells with stronger inhibitory effect. EAE was induced in C57BL/6N
mice and 16106 of IgG-NK cells or untreated-NK cells were injected intravenously at the day of EAE induction. (A, B) Cells were isolated from draining
LNs 10 days after EAE induction and analyzed by Flow cytometry. Treg cells were identified by intracellular expression of Foxp3 on the gated CD4+
cells. Data are displayed as the mean percentage 6 SEM of the combined data with 4–6 mice per group from 2 independent experiments. (C, D)
26104 CFSE-labeled CD4+CD252 T cells from the spleen of immunized EAE mice were cocultured with 16104 irradiated CD42 depleted splenocytes.
CD4+CD25hi T cells from EAE mice (TregEAE), NK treated EAE mice (TregNK-EAE) or IgG-NK treated EAE mice (TregIgG-NK-EAE) were added according to
indicated ratios with MOG35–55. The intensities of CFSE were determined at day 5 by FACS. CD4
+CD25hi Treg cells from EAE mice with IgG-NK cell
treatment displayed stronger suppressive effect (p, 0.05). Mice: n = 4 per group. (E) Treg cells were depleted by injection of 100 mg of anti-CD25
antibody (PC61) intravenously 2 days before EAE induction. 16106 of IgG-NK cells were injected intravenously at the day of EAE induction. The mean
clinical scores of EAE mice with IgG-NK cell treatment were significantly lower but it was reversed by anti-CD25 antibody treatment. Mice: n = 4 per
group. Data are representative of at least 2 independent experiments and displayed as the mean 6 SEM. *: p,0.05; **: p,0.01, Krusaki-Wallis test.
doi:10.1371/journal.pone.0060862.g004
IgG-NK Induces Treg to Suppress EAE
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expressed by NK cells may also be involved in the induction. IL-2
and plate-bound anti-CD16 activate NK cells to express CD86 for
co-stimulating IL-2 production and proliferation in CD4+ T cells
[9,22]. Plate-bound anti-CD16 activates NK cells to express
another T cell co-stimulatory molecule, i.e. OX40-ligand [22],
which can deliver a survival signal to Treg cells [23]. However,
IgG did not induce NK cells to express CD86 and OX40-ligand
(data not shown), excluding the role of these two co-stimulatory
molecules in inducing Treg by IgG-NK cells. Interestingly, IL-2-
activated NK cells are shown to suppress Foxp3 expression in
CD4+CD252 T cells, which is different from our observation that
IgG-NK cells induce Foxp3 expression [24]. These suggest that
upon different stimulations, NK cells display distinct regulatory
roles in Treg induction.
An alternative mechanism underlying the role of NK cells in the
efficacy of IVIG treatment was recently proposed on the basis of in
vitro studies [25]. Tha-In et al. demonstrated that NK cells
suppress T-cell priming by mediating antibody-dependent cellular
cytotoxicity (ADCC) to IVIG-treated DCs and this ADCC is
induced by IgG via CD16, the low affinity Fcc receptor, on NK
cells [25]. Although we have demonstrated that NK cells induce
Treg cells to ameliorate EAE during IgG treatment (Figure 1 and
3), our data in no way exclude direct killing of IgG-primed antigen
presenting cells (APCs) by NK cells as another mechanism through
which NK cells could suppress autoimmune disease, since this
could inhibit the presentation of autoantigen to self-reactive T
cells. Future in vivo studies are needed to examine the possible role
of ADCC-driven elimination of APCs by NK cells in IgG
treatment.
IVIG can also directly regulate NK cells cytotoxicity and
cytokine production. Recent studies demonstrated that IVIG
suppresses NK cells cytotoxicity towards two cancer cell lines, i.e.
K562 and A431 by exhausting the NK cell cytotoxicity machinery
via spontaneous degranulation. IVIG also activates them to
produce more IFN-c [26,27]. This may contribute to the
therapeutic effect of IVIG because IFN-c suppresses Th17
responses, which is critical in promoting autoimmune diseases
[28]. These studies also demonstrated that the number of
peripheral NK cells number drop significantly in patients after
IVIG treatment [26,27], indicates that IVIG may induce the tissue
redistribution of NK cells, as they express different chemokine
receptors for migration to inflammatory site and secondary
lymphoid organs [29].
A number of studies that investigated the function of NK cells in
EAE reported contradictory results [30–33]. Hao et al. [30]
recently reported that NK cells are required to suppress Th17
induction by microglia in CNS of EAE mice. However, Winkler-
Pickett et al. [33] demonstrated that depletion of NK cells is
protective in EAE mice and is associated with less DCs maturation
and a reduction in pathogenic T cells accumulation. In the present
study we did not observe a discernible difference in clinical scores
between the EAE mice with or without NK cell depletion
(Figure 1A). This can be explained by the timing of NK cell
depletion in these studies [30–33]. As we only focus on the period
during IgG treatment (2 doses on day 0 and 4), we only depleted
NK cells by anti-asialos GM-1 antibody 1 day before the
administration of IgG (2 doses on day 21 and 3), limiting the
period of NK deficiency to coincide with IgG treatment. The
other studies depleted NK cells throughout the entire experiments,
affecting also the later period where NK cells could be involved in
effector mechanisms of disease during later phases of EAE
development.
Direct stimulatory effects of Treg cells by IVIG in vitro were also
reported [15,34]. Ephrem et al. (2008) showed that mouse Treg
cells increase their proliferation when cultured with IVIG.
Another study also reported that coculture of human Treg cells
with IVIG enhance their TGF-b and IL-10 production [34]. We
cannot exclude the possibility that IVIG could directly stimulate
Treg cells in vivo, however, we demonstrated that if NK cells were
depleted, the beneficial effect of IgG on disease as well as the
expansion of Treg cells in vivo are prevented (Figures 1 and 3).
These results lead to the conclusion that NK cells mediate the
effect of IVIG treatment in suppressing EAE at least in part by
inducing Treg cells in vivo.
Figure 5. IgG-NK cells induce CD4+Foxp3+ Treg cells and antigen specific T cells to express higher CD25 and IL-2 respectively. EAE
was induced in C57BL/6N mice and 16106 of IgG-NK cells or untreated-NK cells were injected intravenously at the day of EAE induction. (A) 10 days
after EAE induction, cells were isolated from draining lymph nodes and 2.56106 isolated cells were re-stimulated with MOG35–55 for 72 hours.
Supernatant was collected and the IL-2 levels were studied by ELISA. IL-2 production was significantly increased after adoptive transfer of IgG-NK cells
(p,0.05) (n = 5–7). Krusaki-Wallis test. (B) Cells were isolated from draining lymph nodes 10 days after EAE induction and studied by FACS.
CD4+Foxp3+ Treg cells from EAE mice (TregEAE) and IgG-NK treated EAE mice (TregIgG-NK-EAE) were gated and the expression of CD25 was shown.
TregIgG-NK-EAE expressed significantly higher CD25 when compared with TregEAE (n = 4). Data are pooled from 2 independent experiments and
displayed as the mean 6 SEM. *: p,0.05. Mann-Whitney-U-Test.
doi:10.1371/journal.pone.0060862.g005
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We observed that NK cells play a critical role in ameliorating
EAE by IgG treatment, with lower Th1 and Th17 immune
response (Figure 2B) and increased Treg cells (Figure 4A and B) in
the draining lymph nodes. However, CNS is unique compared to
peripheral compartment [35] and how NK cells regulate T cell
response in CNS during IgG treatment on EAE mice should be
investigated in the future.
Interestingly, we observed that NK cell depleted mice produced
more IL-17 after treatment with IgG (Figure 1B). Innate IFN-c has
been implicated in suppressing Th17 response and related tissue-
specific autoimmunity. Depletion of NK cells, which are the major
source of innate IFN-c, may lead to upregulation of IL-17
response in IgG-treated mice. However, similar phenomenon was
not observed in NK cell depleted mice without IgG treatment
(Figure 1B). Further investigation is required to study the effect of
IgG in IL-17 response in NK cell depleted mice.
We demonstrated that Treg cells are required for the observed
protective effect of IgG-NK cells on EAE by depleting Treg cells in
IgG-NK treated group with anti-CD25 antibody (Figure 4E).
Previous study also demonstrated that Treg cells are critical to
suppress EAE by IVIG [15]. Although the use of anti-CD25
antibody to deplete Treg cells is widely accepted, it should be
noted that most of the activated lymphocytes, including effector T
cells, activated NKT cells and NK cells expressed CD25. Ligation
of CD25 may result in cellular depletion and/or functional
modulation on these cells.
IVIG has been shown to be effective against different
autoimmune diseases. Although we and others clearly demon-
strated that IgG and IVIG suppresses EAE [2,25], therapeutic
efficacy of IVIG in treating multiple sclerosis is still controversial.
EAE is used for the experimental model for multiple sclerosis
because they have similar pathological features, including CNS
inflammation and demyelination. However, EAE is an artificial
animal model with different immunopathogenic mechanisms to
multiple sclerosis. It is known that EAE is mainly CD4+ Th1 and/
or Th17 pathogenic T cells driven, but CD8+ T cells are much
Figure 6. IgG-NK cells induce naı¨ve CD4+CD62L+ T cells to convert into CD4+Foxp3+ Treg cells in the presence of IL-2 and TGF-b1. (A,
B) 16106 naı¨ve CD4+CD62L+ T cells purified from spleens of naı¨ve mice were cultured with plate-bound anti-CD3 and soluble anti-CD28 antibodies.
16106 isolated NK cells or IgG-NK cells were added to the culture with or without low dose of TGF-b (0.1 ng/ml) for 4 days. (B) 10 mg/ml of anti-IL-2
antibody or isotype control was added to neutralize IL-2. Data displayed as the mean 6 SEM from 4 independent experiments. *: p,0.05. Mann-
Whitney-U-Test.
doi:10.1371/journal.pone.0060862.g006
IgG-NK Induces Treg to Suppress EAE
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more dominant in multiple sclerosis [36]. Nevertheless, we
demonstrated that IgG ameliorates EAE and its efficacy is
dependent on NK cells. Future studies are required to translate
this observation into multiple sclerosis and other human autoim-
mune diseases.
We demonstrated that the increased induction of Foxp3+ Treg
cells from naı¨ve T cells by IgG-NK cells is depended on IL-2 by
using IL-2 neutralization antibody (Figure 6). Treg cells constitu-
tively express high level of high affinity IL-2 receptor, CD25, while
NK cells usually expresse low affinity IL-2 receptor [37]. High
level of IL-2 is crucial for Treg growth, survival and expansion
[38]. IL-2 also induces NK cells activation and proliferation [39].
Therefore, neutralizing IL-2 in NK-T cells coculture may affect
both NK and T cells and resulted in lower Treg conversion.
IVIG consists of the polyclonal IgG pooled from the sera of
different donors, including different polyreactive natural antibod-
ies and antigen specific antibodies. During the production process,
IgG are modified and stabilizers are also used to prevent IgG
aggregation that may trigger non-specific complement activation
or other pro-inflammatory response. In this study, we used
unmodified human IgG in our EAE model. Although there are
possibilities that our IgG is more ‘‘proinflammatory’’ when
compared to IVIG, we demonstrated that it suppressed EAE
development (Figure S7) and induced Foxp3+ Treg cells in EAE
mice (Figure 3), similar to IVIG [15].
In conclusion, we report a pivotal role for NK cells in
suppressing EAE by IgG treatment through induction of Treg
cells. Future studies should be carried out to confirm our
observation in humans being treated for autoimmune diseases by
IVIG and this may provide further hints in how best to use IVIG
as a therapeutic. Importantly, we identify a novel function of NK
cells in peripheral tolerance as inducers of CD4+Foxp3+ Treg cells.
These observations provide a new insight into the role of NK cells
in regulating adaptive immunity, immune tolerance and hence
autoimmune diseases.
Materials and Methods
EAE induction and assessment
Eight to twelve weeks old C57BL/6N mice obtained from
Laboratory of Animal Unit, The University of Hong Kong were
used in the experiments. In some experiments, C57BL/6 mice
were purchased from The Jackson Laboratory (Bar Harbor, ME).
These mice were kept in a specific pathogen-free facility in
National Institues of Health. EAE was induced by subcutaneous
injection of 200 ml of emulsion containing 200 mg of myelin
oligodendrocyte glycoprotein peptide fragment 35–55 (MOG35–55)
(MEVGWYRSPFSRVVHL-YRNGK) (Chinese Peptide Compa-
ny, Zhejiang, China) in complete Freund’s adjuvant with 400 mg
of H37Ra Mycobacterium tuberculosis (Difco Laboratories,
L’Arbresk, France). 400 ng of pertussis toxin (Calbiochem, San
Diego, CA) was injected intravenously on day 0 and 2. All
procedures were approved by the Committee on the Use of Live
Animals in Teaching and Research of the University of Hong
Kong and by the Animal Care and Use Committee of the
National Eye Institute.
Disease severity was assessed daily in a blinded fashion as
described previously [40]. Briefly, scores were assigned as follows:
0: no clinical sign; 1: weakness of the tail; 2: complete tail paralysis;
3: partial hind limb paralysis; 4: complete hind limb paralysis; 5:
incontinence and partial or complete paralysis of forelimbs; 6:
death.
IgG treatment
10% IgG was freshly prepared from human serum IgG
(Calbiochem, San Diego, CA) in PBS. This IgG is bioequivalent
to the commercially available IVIG (Gamunex, Talecris Biother-
apeutics) in terms of suppressing EAE (Figure S7). Human IgG or
commercially available IVIG was injected intravenously on the
same day and 4 days after immunization at a dose of 1g/Kg [14].
In vivo depletion of NK cells and Treg cells
To deplete NK cells in vivo, mice were injected intravenously
with 50 ml of anti-asialo GM1 antibody (Wako, Richmond, VA) 1
day before and 3 days after immunization. For Treg depletion,
100 mg of anti-CD25 antibody, PC61 (Biolegend, San Diego, CA),
in 100 ml of PBS was injected intravenously 2 days before
immunization.
Adoptive transfer of NK cells
NK cells were negatively selected from splenocytes by NK
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
They were cultured with or without 10 mg/ml of IgG (Calbio-
Figure 7. CD4+CD25hi Treg cells induced by IgG-NK cells suppresses CD4+ T cells proliferation. (A, B) CD4+CD25hi Treg cells was induced
by coculturing IgG-NK cells and CD4+CD62L+ T cells and sorted by FACS. 26104 CFSE-labeled CD4+CD62L+ T cells were cocultured with the sorted
CD4+CD25hi T cells according to the indicated ratios. Plate bound anti-CD3 and soluble anti-CD28 antibodies were used to stimulate T cell
proliferation. The intensities of CFSE were determined at day 4 by flow cytometry. CD4+CD25hi Treg cells significantly suppressed CD4+ T cells
proliferation at 1 to 1 ratio (p,0.01). Representative of 4 independent experiments (A); Data pooled from 4 independent experiments (B).
doi:10.1371/journal.pone.0060862.g007
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chem) for 18 hours and then the NK cells were washed with PBS
for 2 times to remove the IgG. 16106 of untreated NK cells or
IgG-NK cells were injected intravenously on the same day of
immunization.
Measurement of secreted cytokines
Cells from draining lymph nodes of the site of immunization
were isolated 10 days after EAE induction. 2.56106 cells were
cultured with 20 mg/ml of MOG35–55 in 1 ml of RPMI containing
10% of fetal calf serum (FCS) for 72 hours. Supernatants were
collected and the levels of cytokines were determined by
Flowcytomix (Bender Medsystems, Vienna, Austria).
Surface and intracellular staining of Treg cells for flow
cytometry analysis
Cells were surface stained with anti-mouse CD4 FITC (RM4-5)
and anti-mouse CD25 APC (PC61.5), fixed and permeabilized
according to the manufacturer’s protocol (Anti mouse Foxp3
staining set, eBioscience, San Diego). Then, cells were stained for
intracellular Foxp3 PE (150D/E4). All antibodies were purchased
from eBioscience. Treg cells were identified by Foxp3 expression
in gated CD4 cells.
T cell suppression assay
CD4+CD252 T cells, CD4+CD62L+ T cells and CD4+CD25hi
T cells were sorted by FACSAria. CD4+CD252 T cells and
CD4+CD62L+ T cells were labeled with CFSE before activation.
26104 labeled CD4+CD252 T cells were activated with 16104
irradiated CD42depleted splenocytes with MOG35–55. 2610
4
labeled CD4+CD62L+ T cells were activated with plate bound
anti-CD3 and anti-CD28 antibodies. CD4+CD25hi T cells were
added at the indicated ratios for 4–5 days. Cell division by CFSE
dilution was analyzed.
In vitro induction of CD4+Foxp3+ cells
Naı¨ve CD4+CD62L+ T cells were isolated from the spleen of
naı¨ve C57BL/6N mice by CD4+CD62L+ T Cell Isolation Kit II
(Miltenyi). 16106 isolated naı¨ve CD4+CD62L+ T cells were
activated with plate-bound anti-CD3 and soluble anti-CD28
antibodies. 16106 isolated untreated NK cells or IgG-NK cells
were added to the culture with or without TGF-b (0.1 ng/ml) for 4
days. In some cases, 10 mg/ml of anti-IL-2 antibody or isotype
control antibody was added to the culture.
Perfusion and Tissue Processing
At the end of the experiment (day 15), the animals were given a
lethal dose of sodium pentobarbital and perfused intracardially
with normal saline followed by perfusion with 200 to 300 ml of
fixative containing 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4). The lumbar spinal cords were harvested and post-
fixed in 2% paraformaldehyde with 2.5% glutaraldehyde over-
night at 4uC. In the following day, samples were treated with 1%
osmium tetroxide for 4 hours, dehydrated in a series of graded
ethanol, cleared in propylene oxide and embedded in pure Epon.
One micrometer semi-thin sections were cut by an ultramicrotome
(Leica, Germany), mounted on gelatin-coated glass slides and
stained with 1% toluidine blue to visualize the myelin.
Statistical analysis
Mann-Whitney-U-Test was used for two groups comparison
and Krusaki-Wallis test was used when more than two groups are
shown. P value of 0.05 was used to indicate significance.
Supporting Information
Figure S1 Depletion of NK cells in vivo by anti-asialo
GM1 antibody. NK cells were depleted as described in Methods
and Materials. The percentage of NK cells in different tissues, i.e.
blood, lymph node and spleen, were determined at different time
point. Nearly 90% of NK1.1+CD32 NK cells were depleted.
Data are displayed as mean6 SEM of 4 mice per each time point.
(TIF)
Figure S2 Comparison of IgG and BSA in treating EAE.
EAE was induced as described in Materials and Methods. IgG and
BSA was injected intravenously at day 0 and 4 (n = 10). Data are
pooled from 2 independent experiments.
(TIF)
Figure S3 Cytokines productions of EAE mice. EAE was
induced in C57BL/6 mice. Untouched NK or IgG-NK cells were
adoptive transferred as described in Methods and Materials. At
day 10, cells were isolated from draining LNs. 2.56106 isolated
cells were re-stimulated with MOG35–55 (20 mg/ml) for 72 hours.
Cytokine productions were determined. Data are displayed as
mean 6 SEM from 2 independent experiments with total of 4–7
mice per group.
(TIF)
Figure S4 Demyelination is reduced in EAE mice after
IgG or IgG-NK cell treatment. Toluidine blue staining of
1 mm semi-thin sections were used to visualize myelination of EAE
mice with different treatments at day 15: (A) Untreated EAE mice;
EAE mice treated with (B) IgG; (C) anti-asialo GM1 antibody; (D)
IVIG and anti-asialo GM1 antibody; (E) untouched NK cells; (F)
IgG-NK cells. When compared with (A) untreated EAE mice,
mice treated with (B) IgG or (F) IgG-NK cell showed decrease in
demyelination. The scale bar is 400 mm for A–F, 80 mm for A1–
F1, 15 mm for A2–F2. Representative of 4 mice for each condition.
(TIF)
Figure S5 Expression of Foxp3 in sorted CD4+CD25hi T
cells. EAE was induced in naı¨ve mice. Untouched NK or IgG-
NK cells were adoptive transferred as described in Methods and
Materials. At day 10, cells were isolated from spleen.
CD4+CD25hi T cells were sorted and stained for Foxp3. More
than 95% of these sorted cells were Foxp3+.
(TIF)
Figure S6 Depletion of Treg cells in vivo by anti-CD25
antibody (PC61). Treg cells were depleted as described in
Methods and Materials. The percentage of CD4+Foxp3+ cells in
different tissues, i.e. blood, lymph node and spleen, were
determined at different time point. Nearly 90% of CD4+Foxp3+
Treg cells were depleted. Data are displayed as mean 6 SEM of 4
mice per each time point.
(TIF)
Figure S7 Comparison of IVIG from different sources
in treating EAE. IVIG prepared from Calibochem is bioequiv-
alent to commercially available IVIG, Gamunex, in suppressing
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